> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info on Review Transparency for New Molecular Entities Sent to OMB
- URL: https://www.fdaweb.com/info-on-review-transparency-for-new-molecular-entities-sent-to-omb/
- Published: 2016-07-21T12:00:00.000Z
- Updated: 2026-09-14T21:16:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136249

*Federal Register* Notice: FDA’s proposed collection of information, “Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Acts,” has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-07-21/pdf/2016-17185.pdf?ref=fdaweb.com)